Foley Hoag has a long history of extensive involvement with the development of legislation and regulations affecting the biotechnology, pharmaceutical, medical device and healthcare provider industries. Our clients include a number of leading pharmaceutical, biotechnology and medical device companies regarding government strategies for legislative, regulatory and administrative matters.
-
Foley Hoag Expands Government Strategies Team
[Read More]
-
Foley Hoag Lawyers in Chambers USA 2010
[Read More]
-
Foley Hoag Launches Healthcare Law and Policy Blog
[Read More]
Publications more
- Healthcare Alert - Interim Final Rules on Preexisting Condition, Lifetime & Annual Limits, Rescissions, and other Patient Protections [Read More]
- ONC Establishes Temporary Certification Program for EHR Technology [Read More]
- Healthcare Alert - Interim Grandfather Rule Summary [Read More]
- Phase II of the FDA’s Transparency Initiative: The Transparency Task Force Releases Draft Recommendations on FDA’s Public Disclosure Policies [Read More]
- Healthcare Alert - CMS Guidance on Implementation of Reduction in Coverage Gap [Read More]
Client Successes more
-
Orphan Drug Act
Our lawyers represented clients under the Orphan Drug Act, which is credited with giving rise to the biotechnology industry, through its provision of seven years of marketing exclusivity to companies that develop drugs or biologics for patients with rare diseases. [Read More]
-
Reimbursement Strategies in the Fight Against Cancer
We represented a leading biotechnology company in increasing hospital outpatient reimbursement for supportive anti-cancer therapy. [Read More]